培塞利珠单抗治疗慢性斑块状银屑病:3期多中心随机双盲依那西普和安慰剂对照研究(CIMPACT)48周结果
这项3期多中心随机双盲对照研究评估培塞利珠单抗治疗中重度慢性斑块状银屑病的安全性和疗效。患者按3:3:1:3随机接受培塞利珠单抗400 mg、200 mg每2周、安慰剂每2周共16周或依那西普50 mg每周两次共12周。第12周时培塞利珠单抗所有终点均显著优于安慰剂,400 mg应答最高;400 mg优于依那西普,200 mg非劣于依那西普。不良事件与抗肿瘤坏死因子类药物一致,未观察到新安全性信号。
要点
- 第12周培塞利珠单抗所有终点均显著优于安慰剂,400 mg应答最高。
- 培塞利珠单抗400 mg优于依那西普,200 mg非劣于依那西普。
- 不良事件与抗肿瘤坏死因子类药物一致,未观察到新安全性信号。
核心结论
- 两种培塞利珠单抗方案均改善银屑病症状,较高剂量应答更明显。
- 未观察到新的安全性信号。
研究设计与样本
- 3期多中心随机双盲依那西普和安慰剂对照研究。
- 患者按3:3:1:3随机接受培塞利珠单抗400 mg、200 mg每2周共16周、安慰剂每2周共16周或依那西普50 mg每周两次共12周。
- 第16周达到PASI较基线下降≥75%的培塞利珠单抗治疗患者再次随机接受培塞利珠单抗或安慰剂共32周。
- 主要终点为第12周应答率(PASI较基线下降≥75%)对比安慰剂(主要分析)和依那西普(次要分析)。
主要发现
- 第12周培塞利珠单抗所有终点均显著优于安慰剂,400 mg应答最高。
- 培塞利珠单抗400 mg优于依那西普,200 mg非劣于依那西普。
- 不良事件与抗肿瘤坏死因子类药物一致。
局限性
- 依那西普由非盲研究 staff 给药或自行给药,但疗效评估由盲法评估者完成。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Phase 2 psoriasis studies with the Fc-free, PEGylated, anti-tumor necrosis factor biologic certolizumab pegol demonstrated meaningful clinical activity. OBJECTIVE: Assess safety and efficacy of certolizumab in adults with moderate-to-severe chronic plaque psoriasis. METHODS: Patients were randomized 3:3:1:3 to certolizumab 400 mg, certolizumab 200 mg, or placebo every 2 weeks for 16 weeks or etanercept 50 mg twice weekly for 12 weeks. Certolizumab-treated patients achieving a ≥75% reduction in Psoriasis Area and Severity Index (PASI) at week 16 from baseline PASI were rerandomized to certolizumab or placebo for 32 weeks. The primary endpoint was responder rate (≥75% reduction in PASI from baseline PASI) versus placebo (primary analysis) and etanercept (secondary analysis) at week 12; secondary endpoints included responder rates on various measures versus placebo at weeks 12, 16, and 48. Safety was assessed by treatment-emergent adverse events. RESULTS: All endpoints were significantly greater for certolizumab versus placebo with the greatest response seen with 400 mg. Certolizumab 400 mg was superior to and 200 mg was noninferior to etanercept. Adverse events were consistent with the anti-tumor necrosis factor class of drugs. LIMITATIONS: Etanercept was administered by unblinded study staff or self-administered, but efficacy assessments were performed by a blinded assessor. CONCLUSION: Both certolizumab regimens improved psoriasis symptoms, with a greater response seen with the higher dose. No new safety signals were observed.
引用
- Lebwohl M, Blauvelt A, Paul C, et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT). J Am Acad Dermatol. 2018. PMID: 29660425. doi:10.1016/j.jaad.2018.04.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。